Uot Beinga Leading Player In The Cardiac Segment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mumbai (Maharashtra) [India], December 5 (ANI/PRNewswire): JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest-growing pharmaceutical companies in India, announced a substantial price decrease of approximately 50 per cent for the critical heart failure drug 'Azmarda'. Azmarda, which contains the patented molecule Saccubutril-Valsartan is indicated for Heart failure which ails 8 to 12 million people in the country. After the price reduction, Azmarda (Saccubutril-Valsartan), 50 mg will be available at Rs 39.6 per tablet as compared to Rs 78 per tablet. Commenting on the move, Dilip Singh Rathore, President - Domestic Business, JB Pharma, said, "Being a leading player in the cardiac segment, JB has decided to take the lead in making their Azmarda drug more accessible and affordable for heart failure patients in India. This is in line with our strategy of providing innovative and quality treatment to a larger patient pool at the most affordable price points. ....

South Africa , United States , Dilip Singh Rathore , Azmarda Saccubutril Valsartan , Jb Chemicals Pharmaceuticals Ltd Pharma , Pharmaceuticals Ltd , Left Ventricular , Heart Failure Reduced Ejection Fraction , Heart Failure Preserved Ejection Fraction , Angiotensin Receptor Blockers , Ace Inhibitors , Rejection Fraction , Mumbai Maharashtra India , Ecember 5 Ani Prnewswire Jb Chemicals Amp Pharmaceuticals Ltd Pharma , Ne Of The Fastest Growing Pharmaceutical Companies In India , Nnounceda Substantial Price Decrease Of Approximately 50 Per Cent For The Critical Heart Failure Drug 39 Azmarda , Hich Contains The Patented Molecule Saccubutril Valsartan Is Indicated For Heart Failure Which Ails 8 To 12 Million People In Country After Price Reduction , Zmarda Saccubutril Valsartan , 0 Mg Will Be Available At Rs 39 6 Per Tablet As Compared To 78 Commenting On The Move , Dilip Singh Rathore , Resident Domestic Business , Jb Pharma , Uot Beinga Leading Player In The Cardiac Segment , B Has Decided To Take The Lead In Making Their Azmarda Drug More Accessible And Affordable For Heart Failure Patients India This Is Line With Our Strategy Of Providing Innovative Quality Treatment Toa Larger Patient Pool At Most Price Points Move , He Overall Monthly Treatment Cost Will Reduce Significantly From Rs 4500 To 2200 The Hf Drug Also Helps In Reducing Hospitalization By Around 1 , 000 At The Minimum Quot He Further Added ,